JP2023550632A - 眼の症状を処置するための製剤および方法 - Google Patents

眼の症状を処置するための製剤および方法 Download PDF

Info

Publication number
JP2023550632A
JP2023550632A JP2023530994A JP2023530994A JP2023550632A JP 2023550632 A JP2023550632 A JP 2023550632A JP 2023530994 A JP2023530994 A JP 2023530994A JP 2023530994 A JP2023530994 A JP 2023530994A JP 2023550632 A JP2023550632 A JP 2023550632A
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
administered
azithromycin
subject
avermectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550632A5 (cg-RX-API-DMAC10.html
Inventor
ポール バダウィ，
デイビッド ワイ． バダウィ，
Original Assignee
サイト サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイト サイエンシーズ， インコーポレイテッド filed Critical サイト サイエンシーズ， インコーポレイテッド
Publication of JP2023550632A publication Critical patent/JP2023550632A/ja
Publication of JP2023550632A5 publication Critical patent/JP2023550632A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023530994A 2020-11-23 2021-11-23 眼の症状を処置するための製剤および方法 Pending JP2023550632A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063117393P 2020-11-23 2020-11-23
US63/117,393 2020-11-23
US202163254958P 2021-10-12 2021-10-12
US63/254,958 2021-10-12
PCT/US2021/060653 WO2022109497A1 (en) 2020-11-23 2021-11-23 Formulations and methods for treating conditions of the eye

Publications (2)

Publication Number Publication Date
JP2023550632A true JP2023550632A (ja) 2023-12-04
JP2023550632A5 JP2023550632A5 (cg-RX-API-DMAC10.html) 2024-11-29

Family

ID=81658809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530994A Pending JP2023550632A (ja) 2020-11-23 2021-11-23 眼の症状を処置するための製剤および方法

Country Status (6)

Country Link
US (5) US20220160668A1 (cg-RX-API-DMAC10.html)
EP (1) EP4247367A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023550632A (cg-RX-API-DMAC10.html)
AU (1) AU2021381495A1 (cg-RX-API-DMAC10.html)
CA (1) CA3199736A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022109497A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9095412B2 (en) 2012-03-20 2015-08-04 Sight Sciences, Inc. Ocular delivery systems and methods
US10299958B2 (en) 2015-03-31 2019-05-28 Sight Sciences, Inc. Ocular delivery systems and methods
US11504270B1 (en) 2019-09-27 2022-11-22 Sight Sciences, Inc. Ocular delivery systems and methods
US20220160668A1 (en) 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
US11877954B2 (en) 2022-03-16 2024-01-23 Sight Sciences, Inc. Devices and methods for intraocular tissue manipulation
AU2023270196B2 (en) * 2023-11-20 2025-06-26 Dyer, Gordon Wayne DR Method of Arthropod Egress

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540147A (ja) * 1999-03-31 2002-11-26 インサイト・ビジョン・インコーポレイテッド 眼感染症の局所治療または予防
JP2011527709A (ja) * 2008-07-10 2011-11-04 インスパイアー ファーマシューティカルズ，インコーポレイティド 眼瞼炎の治療方法
JP2014530044A (ja) * 2011-09-14 2014-11-17 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔｖｉｓｉｏｎ５，Ｉｎｃ． 眼挿入装置および方法
JP2017526655A (ja) * 2014-09-06 2017-09-14 インテグラル バイオシステムズ エルエルシー 眼において薬物徐放を達成する方法及び生体適合性組成物

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614545A (en) 1988-06-09 1997-03-25 Leonard Bloom Topical composition for treatment of blepharitis
US4957918A (en) 1988-06-09 1990-09-18 Leonard Bloom Topical treatment of blepharitis
AT393454B (de) 1989-10-04 1991-10-25 Ido Dr Egerer Augentropfenzusatz
US6107289A (en) 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
RU2004118424A (ru) 2001-11-19 2005-05-10 Новартис АГ (CH) Применение аскомицина для лечения блефарита
AR042890A1 (es) 2003-01-16 2005-07-06 Sucampo Pharmaceuticals Inc Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido
KR20050092429A (ko) 2003-01-22 2005-09-21 니찌방 가부시기가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
CA2597525A1 (en) 2005-02-17 2006-08-24 Senju Pharmaceutical Co., Ltd. Solid ophthalmic drug for external use
US20070004672A1 (en) 2005-07-01 2007-01-04 Dharmendra Jani Long lasting alginate dry eye, related methods of manufacture and methods of use
FR2891460B1 (fr) 2005-09-30 2010-07-30 Galderma Sa Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
EP1964575B1 (en) 2005-11-28 2015-09-23 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising ppar agonist
US20090318422A1 (en) 2006-08-28 2009-12-24 Akiharu Isowaki Ophthalmic percutaneous absorption type preparation
US20080057022A1 (en) 2006-08-30 2008-03-06 Erning Xia Ophthalmic Pharmaceutical Compositions and Uses Thereof
US7659259B2 (en) 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
US20080312194A1 (en) 2007-02-28 2008-12-18 Ousler Iii George W Methods and compositions for normalizing meibomian gland secretions
CA2685230C (en) * 2007-05-04 2012-10-16 Bausch & Lomb Incorporated Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same
WO2008137826A2 (en) 2007-05-07 2008-11-13 Bausch & Lomb Incorporated Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same
CA2753844A1 (en) 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
US20110059925A1 (en) 2008-03-26 2011-03-10 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics
WO2010085572A1 (en) 2009-01-23 2010-07-29 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with azithromycin
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
ES2752008T3 (es) 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
WO2011068786A2 (en) 2009-12-02 2011-06-09 Bridge Pharma, Inc. Treating xerophthalmia with compounds increasing meibomian gland secretion
US9011861B2 (en) * 2010-02-25 2015-04-21 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
AU2011287544B2 (en) 2010-08-06 2014-12-11 Galderma Research & Development Combination of compounds for treating or preventing skin diseases
WO2012092375A1 (en) 2010-12-29 2012-07-05 Inspire Pharmaceuticals, Inc. Method for treating dry eye
US8900626B2 (en) 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
WO2013003731A2 (en) 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
EP2895144B1 (en) 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
MX363182B (es) 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
CA2886042C (en) 2012-09-28 2015-11-24 Santen Pharmaceutical Co., Ltd. Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage
US9044508B2 (en) 2013-03-15 2015-06-02 Insite Vision Corporation Concentrated aqueous azalide formulations
US20150141328A1 (en) * 2013-11-18 2015-05-21 The Schepens Eye Research Institute Stimulation of human meibomian gland function
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US9597328B2 (en) * 2015-02-24 2017-03-21 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
US9393243B1 (en) 2015-07-14 2016-07-19 Nilesh Parikh Topical Ciprofloxacin compositions
WO2017055924A2 (en) 2015-09-28 2017-04-06 M.G. Therapeutics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
FR3041540B1 (fr) 2015-09-29 2018-10-26 Galderma Research & Development Composition nettoyante auto-moussante a rincer, contenant de l'ivermectine.
WO2017089980A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic retinopathy and diabetic eye diseases
GB201522144D0 (en) 2015-12-15 2016-01-27 Univ Manchester Compositions and uses and methods relating thereto
US9439917B1 (en) 2015-12-28 2016-09-13 Shetal Amit Shah Anti-blepharitis compositions and their use
EA201891743A1 (ru) 2016-02-04 2019-01-31 Гордон Уэйн Дайер Способ нарушения состояния касси-бакстера
US11260035B2 (en) 2016-10-12 2022-03-01 Ps Therapies Ltd Topical compositions and methods of use thereof
EP3326608A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solid fatty substances
GB201706969D0 (en) 2017-05-02 2017-06-14 Medherant Ltd Formulation
US20190008920A1 (en) * 2017-05-19 2019-01-10 Ocugen, Inc. Ophthalmic compositions and methods of use
EP3644966A4 (en) 2017-06-29 2021-03-24 Advaite LLC TREATMENT AND DIAGNOSIS OF EYE SURFACE DISORDERS
CA3080166A1 (en) 2017-11-21 2019-05-31 Axerovision, Inc. Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
WO2019113475A1 (en) 2017-12-07 2019-06-13 Dermavant Sciences GmbH Topical ointment formulations and their use in treating skin conditions
WO2020077284A1 (en) 2018-10-12 2020-04-16 Hovione Scientia Macrocyclic lactone formulations, methods of their preparation and use of the formulations in treating pathologies secondary to ophthalmic parasites
US12161752B2 (en) * 2019-08-20 2024-12-10 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
US20210052493A1 (en) 2019-08-21 2021-02-25 Joseph Sinclair Non-aqueous anti-parasitic ointment for ophthalmological use
WO2021067823A2 (en) 2019-10-05 2021-04-08 The Schepens Eye Research Institute, Inc. A new treatment for meibomian gland dysfunction
WO2021087051A1 (en) 2019-10-30 2021-05-06 Ps Therapy Ltd. Topical compositions and methods of use thereof
US20220160668A1 (en) 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
US11872213B2 (en) 2021-01-28 2024-01-16 Glaukos Corporation Formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540147A (ja) * 1999-03-31 2002-11-26 インサイト・ビジョン・インコーポレイテッド 眼感染症の局所治療または予防
JP2011527709A (ja) * 2008-07-10 2011-11-04 インスパイアー ファーマシューティカルズ，インコーポレイティド 眼瞼炎の治療方法
JP2014530044A (ja) * 2011-09-14 2014-11-17 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔｖｉｓｉｏｎ５，Ｉｎｃ． 眼挿入装置および方法
JP2017526655A (ja) * 2014-09-06 2017-09-14 インテグラル バイオシステムズ エルエルシー 眼において薬物徐放を達成する方法及び生体適合性組成物

Also Published As

Publication number Publication date
WO2022109497A1 (en) 2022-05-27
US20220160668A1 (en) 2022-05-26
US11419886B2 (en) 2022-08-23
EP4247367A1 (en) 2023-09-27
CA3199736A1 (en) 2022-05-27
US11554134B2 (en) 2023-01-17
US20220354878A1 (en) 2022-11-10
US20240415860A1 (en) 2024-12-19
AU2021381495A1 (en) 2023-06-22
EP4247367A4 (en) 2024-10-16
US20230210878A1 (en) 2023-07-06
US20220160743A1 (en) 2022-05-26
US11925657B2 (en) 2024-03-12

Similar Documents

Publication Publication Date Title
US11925657B2 (en) Formulations and methods for treating conditions of the eye
JP2019518730A (ja) 眼の炎症性障害および疾患の組合せ処置
EP2646010B1 (en) Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions
TWI815423B (zh) 用於治療近視的方法和藥物組合物
JP2023550632A5 (cg-RX-API-DMAC10.html)
JP2023512828A (ja) クロマカリムプロドラッグ療法のための改善された方法及び組成物
US20110217262A1 (en) Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
WO2015187840A2 (en) Methods and formulations for treatment of ocular disorders
EP4011450A1 (en) Ophthalmic composition for promoting tear secretion
KR20210010638A (ko) 다이피리다몰을 이용하여 눈 장애를 치료하는데 사용하기 위한 조성물
US9901580B2 (en) Methods of eye treatment using therapeutic compositions containing dipyridamole
CN116710087A (zh) 用于治疗眼部病症的制剂和方法
CN101432000B (zh) 用于变应性眼病或变应性鼻病的包含三环性三唑并苯并氮杂*衍生物的预防剂或治疗剂
CN108348516A (zh) 外用剂
RS66989B1 (sr) Oftalmološke topikalne formulacije na bazi ksantana sa redukovanim režimom doziranja
RU2836815C1 (ru) Офтальмологические композиции для местного применения на ксантановой основе с сокращенным режимом дозирования
Williams et al. The birth of ocular pharmacology in the 20th century
CN104721820A (zh) 双特异性单克隆抗体在治疗葡萄膜炎中的用途
Mashael Systemic Medications and Their Ocular Side Effects
EA051764B1 (ru) Офтальмологическая композиция, содержащая левофлоксацин и кеторолак, способ ее получения и ее применение
CN117959316A (zh) 一种包含恩格列净的药物组合物及其制备方法与制药用途
Hopkins Therapeutic drugs
HK40070050A (en) Compositions and methods useable for treatment of dry eye
HK40039952A (en) Pharmaceutical compositions for controlling and/or reducing the progression of myopia
EA047371B1 (ru) Применение соединения при лечении сухости глаз или дискомфорта в глазах

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250818

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260311